135 related articles for article (PubMed ID: 27072693)
1. Searching for Therapeutics Against Botulinum Neurotoxins: A True Challenge for Drug Discovery.
Duplantier AJ; Kane CD; Bavari S
Curr Top Med Chem; 2016; 16(21):2330-49. PubMed ID: 27072693
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication.
Li B; Peet NP; Butler MM; Burnett JC; Moir DT; Bowlin TL
Molecules; 2010 Dec; 16(1):202-20. PubMed ID: 21193845
[TBL] [Abstract][Full Text] [Related]
3. Challenges in searching for therapeutics against Botulinum Neurotoxins.
Pirazzini M; Rossetto O
Expert Opin Drug Discov; 2017 May; 12(5):497-510. PubMed ID: 28271909
[TBL] [Abstract][Full Text] [Related]
4. Strategies to design inhibitors of Clostridium botulinum neurotoxins.
Cai S; Singh BR
Infect Disord Drug Targets; 2007 Mar; 7(1):47-57. PubMed ID: 17346211
[TBL] [Abstract][Full Text] [Related]
5. Targeted 8-hydroxyquinoline fragment based small molecule drug discovery against neglected botulinum neurotoxin type F.
Chauhan R; Chauhan V; Sonkar P; Vimal M; Dhaked RK
Bioorg Chem; 2019 Nov; 92():103297. PubMed ID: 31557621
[TBL] [Abstract][Full Text] [Related]
6. Botulinum Neurotoxins: Mechanism of Action.
Rossetto O; Pirazzini M; Fabris F; Montecucco C
Handb Exp Pharmacol; 2021; 263():35-47. PubMed ID: 32277300
[TBL] [Abstract][Full Text] [Related]
7. Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A.
Jacobson AR; Adler M; Silvaggi NR; Allen KN; Smith GM; Fredenburg RA; Stein RL; Park JB; Feng X; Shoemaker CB; Deshpande SS; Goodnough MC; Malizio CJ; Johnson EA; Pellett S; Tepp WH; Tzipori S
Toxicon; 2017 Oct; 137():36-47. PubMed ID: 28698055
[TBL] [Abstract][Full Text] [Related]
8. [Clostridium botulinum and botulinum neurotoxin].
Hirai Y
Brain Nerve; 2011 Jul; 63(7):755-61. PubMed ID: 21747146
[TBL] [Abstract][Full Text] [Related]
9. The long journey of botulinum neurotoxins into the synapse.
Rummel A
Toxicon; 2015 Dec; 107(Pt A):9-24. PubMed ID: 26363288
[TBL] [Abstract][Full Text] [Related]
10. Recent developments with metalloprotease inhibitor class of drug candidates for botulinum neurotoxins.
Kumar G; Swaminathan S
Curr Top Med Chem; 2015; 15(7):685-95. PubMed ID: 25751268
[TBL] [Abstract][Full Text] [Related]
11. Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design.
Agarwal R; Binz T; Swaminathan S
Biochemistry; 2005 Sep; 44(35):11758-65. PubMed ID: 16128577
[TBL] [Abstract][Full Text] [Related]
12. A Novel Inhibitor Prevents the Peripheral Neuroparalysis of Botulinum Neurotoxins.
Azarnia Tehran D; Zanetti G; Leka O; Lista F; Fillo S; Binz T; Shone CC; Rossetto O; Montecucco C; Paradisi C; Mattarei A; Pirazzini M
Sci Rep; 2015 Dec; 5():17513. PubMed ID: 26670952
[TBL] [Abstract][Full Text] [Related]
13. Phosphatase Inhibitors Function as Novel, Broad Spectrum Botulinum Neurotoxin Antagonists in Mouse and Human Embryonic Stem Cell-Derived Motor Neuron-Based Assays.
Kiris E; Nuss JE; Stanford SM; Wanner LM; Cazares L; Maestre MF; Du HT; Gomba GY; Burnett JC; Gussio R; Bottini N; Panchal RG; Kane CD; Tessarollo L; Bavari S
PLoS One; 2015; 10(6):e0129264. PubMed ID: 26061731
[TBL] [Abstract][Full Text] [Related]
14. Partial protection against Botulinum B neurotoxin-induced blocking of exocytosis by a potent inhibitor of its metallopeptidase activity.
Anne C; Turcaud S; Blommaert AG; Darchen F; Johnson EA; Roques BP
Chembiochem; 2005 Aug; 6(8):1375-80. PubMed ID: 15988765
[TBL] [Abstract][Full Text] [Related]
15. Current strategies for designing antidotes against botulinum neurotoxins.
Patel K; Cai S; Singh BR
Expert Opin Drug Discov; 2014 Mar; 9(3):319-33. PubMed ID: 24520991
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore Refinement Guides the Rational Design of Nanomolar-Range Inhibitors of the Botulinum Neurotoxin Serotype A Metalloprotease.
Nuss JE; Dong Y; Wanner LM; Ruthel G; Wipf P; Gussio R; Vennerstrom JL; Bavari S; Burnett JC
ACS Med Chem Lett; 2010 Oct; 1(7):301-305. PubMed ID: 21116458
[TBL] [Abstract][Full Text] [Related]
17. Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity.
Burnett JC; Schmidt JJ; Stafford RG; Panchal RG; Nguyen TL; Hermone AR; Vennerstrom JL; McGrath CF; Lane DJ; Sausville EA; Zaharevitz DW; Gussio R; Bavari S
Biochem Biophys Res Commun; 2003 Oct; 310(1):84-93. PubMed ID: 14511652
[TBL] [Abstract][Full Text] [Related]
18. Small molecule non-peptide inhibitors of botulinum neurotoxin serotype E: Structure-activity relationship and a pharmacophore model.
Kumar G; Agarwal R; Swaminathan S
Bioorg Med Chem; 2016 Sep; 24(18):3978-3985. PubMed ID: 27353886
[TBL] [Abstract][Full Text] [Related]
19. Probing the structure and function of the protease domain of botulinum neurotoxins using single-domain antibodies.
Lam KH; Tremblay JM; Perry K; Ichtchenko K; Shoemaker CB; Jin R
PLoS Pathog; 2022 Jan; 18(1):e1010169. PubMed ID: 34990480
[TBL] [Abstract][Full Text] [Related]
20. Structure-based drug discovery for botulinum neurotoxins.
Swaminathan S
Curr Top Microbiol Immunol; 2013; 364():197-218. PubMed ID: 23239355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
